Trial · NCT02568007
Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders
NCT02568007, Phase 4, Terminated, Medical College of Wisconsin; results first posted 2020-01-31
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders. Trials, record NCT02568007. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02568007
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders
- NCT number
- NCT02568007
- Status
- Terminated
- Phases
- Phase 4
- Enrollment
- 4 participants, actual
- Lead sponsor
- Medical College of Wisconsin
- Conditions
- Feeding Behaviors
- Interventions
- Cyproheptadine
- First posted
- 2015-10-05
- Last updated
- 2020-01-31
- Results first posted
- 2020-01-31
- Limitations and caveats
- Early termination leading to small numbers of subjects analyzed;
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feeding Behavior Questionnaire | two months | Participants' guardians will complete the Mealtime Behavior Questionnaire (MBQ). This is a validated, 31-item, parent-report questionnaire assessing the mealtime behavior structure in young children above 2 years. The questionnaire measures variables including: 1) food refusals/avoidance; 2) food manipulation; 3) mealtime aggression and 4) choking/gagging/vomiting related to meals. Each behavior is assigned a frequency scale with 1 corresponding to "never" and 5 corresponding to "always." The MBQ then consist of a total score and four subcategory scores (listed above). |
| Secondary | Anthropometrics: Skin Fold Thickness | two months | Change in skin fold thickness as measured by centimeters and z-score percentiles |
| Secondary | Anthropometrics: Mid-arm Circumference | two months | Change in mid-arm circumference as measure by centimeters and z-score percentiles |
| Secondary | Anthropometrics: BMI | two months | Change in BMI as measured by kilograms divided by meters squared and z-score percentiles |
| Secondary | Anthropometrics: Height | two months | Change in height as measured in centimeters and z-score percentiles |
| Secondary | Anthropometrics: Weight | two months | Change in weight as measured in kilograms and z-score percentiles |
| Secondary | Percentage of Participants Experiencing Side Effects From Cyproheptadine | two months | Patients will answer affirmative or negative to a descriptive list of side effects commonly experienced when taking cyproheptadine. Examples of these descriptive variables include nausea, emesis, etc. Percentage of patients experiencing each side effect will be calculated and compared across the course of study. |
| Secondary | 24 Hour Diet Recall | two months | Change in calorie intake will be recorded |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Feeding Behavior Questionnaire | two months | Too few patients to analyze | ||
| SECONDARY | Anthropometrics: Skin Fold Thickness | two months | Too few patients to analyze | ||
| SECONDARY | Anthropometrics: Mid-arm Circumference | two months | Too few patients to be analyzed | ||
| SECONDARY | Anthropometrics: BMI | two months | Too few patients to be analyzed | ||
| SECONDARY | Anthropometrics: Height | two months | Too few patients to be analyzed | ||
| SECONDARY | Anthropometrics: Weight | two months | Too few patients to be analyzed | ||
| SECONDARY | Percentage of Participants Experiencing Side Effects From Cyproheptadine | two months | Too few patients to be analyzed | ||
| SECONDARY | 24 Hour Diet Recall | two months | Too few patients to be analyzed |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | No Cyproheptadine Treatment | 2 | |
| Overall Study | STARTED | Continuous Cyproheptadine | 2 | |
| Overall Study | STARTED | Cycled Cyproheptadine | 0 | |
| Overall Study | COMPLETED | No Cyproheptadine Treatment | 2 | |
| Overall Study | COMPLETED | Continuous Cyproheptadine | 2 | |
| Overall Study | COMPLETED | Cycled Cyproheptadine | 0 | |
| Overall Study | NOT COMPLETED | No Cyproheptadine Treatment | 0 | |
| Overall Study | NOT COMPLETED | Continuous Cyproheptadine | 0 | |
| Overall Study | NOT COMPLETED | Cycled Cyproheptadine | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | No Cyproheptadine Treatment | 0 | 2 |
| Total, all-cause mortality | Continuous Cyproheptadine | 0 | 2 |
| Total, all-cause mortality | Cycled Cyproheptadine | 0 | 0 |
| Total, other adverse events | No Cyproheptadine Treatment | 0 | 2 |
| Total, other adverse events | Continuous Cyproheptadine | 0 | 2 |
| Total, other adverse events | Cycled Cyproheptadine | 0 | 0 |
| Total, serious adverse events | No Cyproheptadine Treatment | 0 | 2 |
| Total, serious adverse events | Continuous Cyproheptadine | 0 | 2 |
| Total, serious adverse events | Cycled Cyproheptadine | 0 | 0 |
Source ClinicalTrials.gov
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02568007
GET https://conductscience.org/api/trials/v1/NCT02568007/registered